Proposed monographs for omission from the BP 2023 and the BP (Vet) 2023

The British Pharmacopoeia is continuing to ensure that the publication remains relevant and comprehensive. As part of this work, several monographs included in the BP 2022 publications have been proposed for omission due to the lack of UK based Marketing Authorisation Holders and low usage within the UK. 

The monographs proposed for omission from the BP 2023 are:

Fluocortolone Cream

Fluocortolone Hexanoate

Oxymetholone

Oxymetholone Tablets

Papaveretum

Vancomycin for Oral Solution

The monographs proposed for omission from the BP (Vet) 2023 are: 

Azaperone Injection

Decoquinate

Decoquinate Premix

Fluanisone

Nitroxinil

Nitroxinil Injection

Serum Gonadotrophin Injection

The British Pharmacopoeia is used in many countries and we welcome feedback from national and international stakeholders regarding the proposed omissions. Monographs omitted from the BP 2023 publications will remain available within the BP Archive, which is accessible via the BP Online publication. Such monographs continue to remain in force under the Human Medicines Regulations 2012.

Please send any comments or objections to fiona.swanson@mhra.gov.uk. The deadline for responses is 28^th February 2022.